The "P" in Pfizer Packs a Silent Punch

I cannot help but think of this scene from Golden Girls when it comes to all things Pfizer. 

Inside the VIP arm of Market Chess Subscription Services, PFE has been one of the highlights for us as we have concentrated our ideas and plays on value stocks more than anything else in recent quarters.

Clearly, I would be delusional not to acknowledge PFE receiving a windfall of sorts from the pandemic and its vaccine. And, indeed, just the s morning the FDA granted full approval to Pfizer-BioNTech’s Covid shot, clearing path to more vaccine mandates as well. 

Overall, though, I still expect value-oriented plays to soundly outperform growth in the coming quarters, if not years. And even as the pandemic (hopefully) abates in due time, healthcare value plays should still fare quite well, if only on a relative basis compared to rich growth stocks. 

Interestingly, even with the PFE approval, the virus testing play CODX (below on updated daily chart) is still threatening a short squeeze higher, as is digital vaccine passport play YOU. This is all happening as plays which had rallied at the outset of the pandemic like APT LAKE MARK NBY, have essentially gone limp. 

Clearly, the market is not expecting anything close to the wave of hospitalizations and deaths we saw in the spring 2020. Instead, the market forecast is for vaccines, testing, and proof of vaccine status.